The incidence of the side effect remains extremely rare with only 833 cases being reported worldwide from about 592 million administered doses of the AstraZeneca vaccine.
published on Wednesday, EMA said a causal relationship between the adenovirus-based vaccine and Guillain-Barre Syndrome was “considered at least a reasonable possibility.”
The agency said therefore the condition should be added to the product information as a side effect of the vaccine. The EMA also recommended a warning should be added to inform the vaccine’s recipients to seek medical attention if they develop weakness and paralysis in the extremities that can progress to the chest and face.
The incidence of the side effect remains extremely rare with only 833 cases reported worldwide from about 592 million administered doses of the AstraZeneca vaccine, as of July 25. GBS is a disorder where the body’s immune system attacks the nerves, causing temporary paralysis and breathing difficulties and it has beenGBS as a “very rare” side effect of the Johnson & Johnson single-dose vaccine, which is built on the same adenovirus technology as the AstraZeneca shot. The U.S. Food and Drug Administration also issued a warning in July of an increased risk of developing the neurological disorder with the Johnson & Johnson vaccine.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Vaccines Mandates Work, But They’re Messy BusinessSchool entrance mandates are probably the single most effective thing we’ve done to achieve high vaccination rates in the U.S., one expert tells FiveThirtyEight. “Can you achieve it through voluntary means? No. Not really.'
Read more »
Novavax begins early-stage trial for combined influenza/COVID-19 vaccineVaccine developer Novavax Inc said on Wednesday it has initiated an early-stage study to test its combined flu and COVID-19 vaccine.
Read more »
Novavax begins early-stage trial for combined influenza/COVID-19 vaccineParticipants will receive a combination of the company's COVID-19 vaccine candidate, NVX-CoV2373, and its Influenza shot NanoFlu along with an adjuvant or vaccine booster. 'Combination of these two vaccines...may lead to greater efficiencies for the healthcare system and achieve high levels of protection against COVID-19 and influenza with a single regimen,' Gregory Glenn, President of Research and Development at Novavax, said in a statement. Novavax had said in May it expects seasonal influenza and COVID-19 combination vaccines to likely be critical in combating emerging COVID-19 variants.
Read more »
Fauci on COVID-19 vaccine: ‘The optimal regimen will ultimately be that third shot’Anthony Fauci, President Joe Biden’s chief medical adviser, told NPR that a third booster shot will become the norm.
Read more »
Novavax begins early-stage trial for combined flu/COVID-19 vaccineTrial results are expected in the first half of 2022.
Read more »